PharmacovigilanceOfficial

Portugal approves public funding for Jemperli in first-line pMMR endometrial cancer

🇵🇹 INFARMED · Mon 09 Nov 2026

INFARMED has granted hospital use of dostarlimab with carboplatin and paclitaxel for advanced or recurrent pMMR endometrial cancer and published its public assessment report on Infomed.

Portugal's medicines authority, INFARMED, has approved public funding for Jemperli (dostarlimab) for hospital use. The decision was announced on 9 November 2026, and the outcome is recorded as 'deferimento', meaning the request was granted.

The funded indication covers use in combination with carboplatin and paclitaxel as first-line treatment. It applies to adults with primary advanced or recurrent endometrial cancer who have mismatch repair proficient (pMMR) disease and are candidates for systemic therapy.

INFARMED has made the public report on the assessment available on Infomed, on the medicine's own page. The report can also be found on the agency's page dedicated to funding decisions.

The notice describes a market access outcome only. It does not mention any pharmacovigilance or safety matter, and it gives no details on pricing, conditions of use or the reasoning behind the decision. Those points would need to be checked in the published report.

What it means for your team

  • Market access teams can consult the Infomed report to see the basis for the Portuguese funding decision on dostarlimab in this indication.
  • Funding is limited to hospital use and to the stated population: pMMR, advanced or recurrent endometrial cancer, in combination with carboplatin and paclitaxel, as first-line therapy.
  • The notice raises no safety or pharmacovigilance issues, so no PV action follows from it.

Official source: INFARMED ↗

Article written by VigiEye from the official source (INFARMED). AI-assisted; check the source before acting.

More Pharmacovigilance All →